Applied BioMath, a computational partner applying quantitative methodologies at critical decision points throughout the drug invention process, announced that it will sponsor and present at the Quantitative Systems Pharmacology (QSP) Program at Discovery on Target 2015 on September 23-24 in Boston, MA. Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will present “QSP approaches enabling quantitative decisions in drug discovery from early research to clinical trials” on Thursday September 24, 2015 at 12:10 PM.
Quantitative Systems Pharmacology approaches continue to gain momentum in pharmaceutical and biotech companies due to their potential to save companies significant costs and shorten research timelines. Applied BioMath’s Founders and Top Scientists have been key contributors in industry to such QSP successes for over a decade, and now with its proprietary technology, Applied BioMath brings its experience and unique modeling approach to its collaborators. With a computational platform built specifically for biological systems and high”er”-throughput computing than existing tools, Applied BioMath is delivering prediction approaches, which when validated in the clinic, were proven to be 10x more accurate than accepted industry standards. Dr. Burke’s talk will highlight one successful use of QSP in immuno-oncology.
“I am excited to present the value of how QSP approaches can help our partners make better decisions by quantifying risk and testing hypotheses in silico, early and often. Key here is highlighting how critical this iterative approach can be.”
- Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath
About Applied BioMath
Applied BioMath, helps biotech and pharmaceutical companies reduce late stage attrition and accelerate best-in-class (BIC) drugs using quantitative methodologies. Leveraging biology, high performance computing (HPC), proprietary technology and experience in pharma, Applied BioMath delivers biological insights proven to shorten project timelines, lower costs, and develop BIC drugs. Services include knowledge gap analysis, experiment prioritization and design, BIC drug property and tox predictions, indication and patient selection, and optimal clinical trial design and analysis.
Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.
View PRNewswire Press Release